Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States
Top Cited Papers
Open Access
- 1 October 2003
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 47 (10), 3149-3154
- https://doi.org/10.1128/aac.47.10.3149-3154.2003
Abstract
Candida bloodstream isolates (n = 2,000) from two multicenter clinical trials carried out by the National Institute of Allergy and Infectious Diseases Mycoses Study Group between 1995 and 1999 were tested against amphotericin B (AMB), flucytosine (5FC), fluconazole (FLU), itraconazole (ITR), voriconazole (VOR), posaconazole (POS), caspofungin (CFG), micafungin (MFG), and anidulafungin (AFG) using the NCCLS M27-A2 microdilution method. All drugs were tested in the NCCLS-specified RPMI 1640 medium except for AMB, which was tested in antibiotic medium 3. A sample of isolates was also tested in RPMI 1640 supplemented to 2% glucose and by using the diluent polyethylene glycol (PEG) in lieu of dimethyl sulfoxide for those drugs insoluble in water. Glucose supplementation tended to elevate the MIC, whereas using PEG tended to decrease the MIC. Trailing growth occurred frequently with azoles. Isolates were generally susceptible to AMB, 5FC, and FLU. Rates of resistance to ITR approached 20%. Although no established interpretative breakpoints are available for the candins (CFG, MFG, and AFG) and the new azoles (VOR and POS), they all exhibited excellent antifungal activity, even for those strains resistant to the other aforementioned agents.Keywords
This publication has 49 references indexed in Scilit:
- In Vitro Activities of Caspofungin Compared with Those of Fluconazole and Itraconazole against 3,959 Clinical Isolates of Candida spp., Including 157 Fluconazole-Resistant IsolatesAntimicrobial Agents and Chemotherapy, 2003
- Evaluation of a Method for Identification of Candida dubliniensis Bloodstream IsolatesJournal of Clinical Microbiology, 2003
- In Vitro Activities of 5-Fluorocytosine against 8,803 Clinical Isolates of Candida spp.: Global Assessment of Primary Resistance Using National Committee for Clinical Laboratory Standards Susceptibility Testing MethodsAntimicrobial Agents and Chemotherapy, 2002
- Comparison of Visual and Spectrophotometric Methods of Broth Microdilution MIC End Point Determination and Evaluation of a Sterol Quantitation Method for In Vitro Susceptibility Testing of Fluconazole and Itraconazole against Trailing and Nontrailing Candida IsolatesAntimicrobial Agents and Chemotherapy, 2002
- In Vitro Activities of Posaconazole (Sch 56592) Compared with Those of Itraconazole and Fluconazole against 3,685 Clinical Isolates of Candida spp. and Cryptococcus neoformansAntimicrobial Agents and Chemotherapy, 2001
- Impact of endpoint definition on the outcome of antifungal susceptibility tests with Candida species: 24- versus 48-h incubation and 50 versus 80% reduction in growthMycoses, 2001
- Present status of the detection of antifungal resistance: the perspective from both sides of the oceanClinical Microbiology & Infection, 2001
- Practice Guidelines for the Treatment of CandidiasisClinical Infectious Diseases, 2000
- International surveillance of blood stream infections due to Candida species in the European SENTRY program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agentsDiagnostic Microbiology and Infectious Disease, 1999
- Paradoxical effect of antibioticsJournal of Antimicrobial Chemotherapy, 1982